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ing mediastinal node involvement (N2) in patients
with non–small cell lung cancer (NSCLC). However,
the reliability of CT scanning in predicting N2 disease
is controversial. Various results have been reported
concerning the accuracy of CT scans in diagnosing N2
disease.1-9
Dales and associates10 performed a meta-analysis of
CT accuracy in diagnosing N2 disease in patients with
NSCLC by using data from 42 studies published
between 1980 and 1988. They concluded that the over-
all accuracy of mediastinal CT scanning was only 80%,
with approximately 20% false-positive and 20% false-
negative results. A high false-positive rate reduces
specificity and the positive predictive value, whereas a
high false-negative rate impairs sensitivity and the neg-
ative predictive value of an examination. The high fre-
quency of false-positive and false-negative results sub-
Computed tomographic (CT) scanning is a widelyused noninvasive imaging procedure for diagnos-
Objectives: The reliability of computed tomographic scanning in evaluating
mediastinal node involvement is controversial because of the high false
result rate. We attempted to identify significant factors responsible for false-
positive and false-negative scans.
Methods: From August 1992 through April 1997, 401 patients with lung can-
cer who underwent major lung resection and systematic lymph node dissec-
tion were enrolled in this study. We retrospectively examined mediastinal
node size, tumor location, maximum tumor dimension, the presence or
absence of obstructive pneumonia, atelectasis, pulmonary fibrosis, and
lymph node calcification on contrast-enhanced computed tomographic
scans. We identified clinical and radiologic factors responsible for the false
results by using univariate and multivariable analysis.
Results: Central tumor location proved to be a significant factor of false-pos-
itive scans. Elevated carcinoembryonic antigen level and larger tumor
dimension were significant factors of false-negative scans. In patients with a
peripheral tumor smaller than 40 mm and normal levels of serum carci-
noembryonic antigen, sensitivity, specificity, positive predictive value, and
negative predictive value were 6%, 93%, 8%, and 90%, respectively. The
reliability of computed tomographic scanning in this low-risk subgroup was
high in detecting N0-1 disease but low in diagnosing N2 disease.
Conclusion: It is not possible to accurately diagnose N2 disease by using
lymph node size on computed tomographic scanning alone, especially in
patients with a central tumor, an elevated serum carcinoembryonic antigen
level, or a tumor of 40 mm or larger. A preoperative invasive staging proce-
dure is indicated in these populations and may not be indicated in the popu-
lation with normal computed tomographic scan results without any of these
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stantiated the poor reliability of CT scanning in medi-
astinal lymph node evaluation.
Therefore, we attempted to identify clinical and radi-
ologic factors responsible for false-positive and false-
negative results of CT scanning. We also re-evaluated
the efficiency of CT scans in predicting N2 disease on
the basis of lymph node size, taking these factors into
account.
Methods
From August 1992 through April 1997, 634 patients with
lung cancer underwent surgical intervention at our institute.
Among them, 401 patients who underwent major lung resec-
tion and systematic lymph node dissection were enrolled in
this study. Seven of them underwent preoperative medi-
astinoscopy, which revealed no mediastinal node involve-
ment. The following patients were excluded: (1) patients who
received induction therapy, (2) patients with multiple prima-
ry lung cancers, and (3) patients with a primary tumor direct-
ly invading the mediastinum. The time interval between CT
scanning and surgical dissection was less than 1 month in all
the patients. CT scans were done on an X-Vision/SP system
(Toshiba, Tokyo, Japan), and contiguous 10-mm thick sec-
tions were obtained from the pulmonary apices to the bases in
a supine position at full inspiration. Dynamic incremental
scanning was always performed, and scans were nearly
always obtained after bolus injection of 100 mL of iopamidol
by using an automatic injector.
All CT scans were reviewed by 3 authors (K.T., Y.O., and
K.S.), who were not informed of the surgical outcome, to
obtain the following information: the maximum dimension
and location of the primary lesion, the sizes of mediastinal
lymph nodes, and the presence of obstructive pneumonia,
atelectasis, pulmonary fibrosis, or lymph node calcification.
If multiple nodes within a single station were enlarged, the
size of the largest node was recorded. The location of a tumor
was considered to be central when it was located in the inner
one third of the lung field on CT scanning and peripheral
when in the outer two thirds. Histologic typing was deter-
mined according to the World Health Organization classifica-
tion.11 The stage of the disease was based on the TNM clas-
sification of the International Union Against Cancer
(UICC).12 The mediastinal lymph node evaluation on CT
scanning and node mapping on thoracotomy were based on
Naruke’s lymph node mapping.13 All resected lymph nodes
were fixed in formalin and examined microscopically by
means of standard hematoxylin and eosin stain. Clinical N2
disease was defined when any mediastinal lymph node was
1.0 cm or larger in the shortest dimension. Pathologic N2 dis-
ease was defined when any mediastinal node was histologi-
cally involved. A true-positive result was documented when a
patient had both clinical N2 and pathologic N2 findings.
The clinical record of each patient was reviewed for age,
sex, histologic typing, smoking status, and serum carcinoem-
bryonic antigen (CEA) level. Serum CEA was measured by
means of the two-site immunoenzymometric assay (Tosoh
Inc, Yamaguchi, Japan), and the upper normal limit for this
assay was 5 ng/mL.
Univariate and multivariable analyses were performed by the
logistic regression procedure on StatView 5.0 software (SAS
Institute, Inc, Cary, NC) with a Macintosh Performa 6420 com-
puter (Apple Computer, Cupertino, Calif) to determine the rela-
tionship between false-positive and false-negative scans and the
following clinical or radiologic findings: age, sex, smoking sta-
tus (pack-years >40 vs ≤40), histologic typing (squamous cell
carcinoma vs others), serum CEA level, tumor location, maxi-
mum tumor dimension, the presence or absence of obstructive
pneumonia, atelectasis, pulmonary fibrosis, and lymph node
calcification on CT scan. The variables, such as age, node, and
tumor dimension, were not skewed. The serum CEA level and
smoking (pack-years) were severely skewed. Thus, we used the
continuous variables for age, node, tumor dimension, and the
log-transformed serum CEA level. For smoking status, we used
the categories of pack-years of greater than 40 versus pack-
years of 40 or less because the pack-years showed a two-peak
distribution. The potential factors of false results in univariate
analyses were also evaluated by using multivariable analyses.
Differences were considered statistically significant when the P
value was less than .05.
Results
The clinical characteristics of the patients are pre-
sented in Table I, and the radiologic characteristics of
the tumors are presented in Table II. There were 57
(14%) cases of false-positive scans and 56 (14%) cases
of false-negative scans.
Univariate analysis revealed 9 potential factors for
false-positive scans (Table III): age, sex, smoking status,
serum CEA level, histology, tumor location, obstructive
pneumonia, atelectasis, and lymph node calcification. In
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Table I. Clinical characteristics of patients
Overall FP FN
No. of patients 401 57 56
Age, y (mean ± SD) 63 ± 10 66 ± 9 63 ±10
Sex (M/F) 245/156 46/11 32/24
Smoking, pack-years (median) 29 41 34
25th-75th percentile (0-50) (14-55) (0-52)
Pack-years >40 134 29 22
Pack-years ≤40 267 28 34
CEA, ng/mL (median) 11.7 10.8 22.1
25th-75th percentile 2.5-7.3 3.1-10.0 3.4-11.2 
Histologic typing
Adenocarcinoma 290 29 44
Squamous cell carcinoma 85 19 11
Large cell carcinoma 15 3 0
Adenosquamous cell carcinoma 11 6 1
FP, False-positive scans; FN, false-negative scans; CEA, carcinoembryonic
antigen.
multivariable analysis only tumor location proved to be a
significant factor of false-positive scans. Lymph node
calcification was a marginally significant factor (P = .06,
Table IV). Patients with central-type lung cancer were
prone to be overestimated as having N2 disease.
Univariate analysis revealed two potential factors of
false-negative scans: serum CEA level and maximum
tumor dimension on CT scan (Table V). These potential
factors were also significant in multivariable analysis
(Table VI).
In patients with a central tumor, the false-positive
rate was 32%. In patients with an elevated CEA level,
the false-negative rate was 18%, and in patients with a
tumor 40 mm or larger in the maximum dimension, it
was 20%. The reliability of CT scanning was poor in
these populations (Tables VII and VIII).
In patients with a peripheral tumor smaller than 40
mm and a normal serum CEA level, both the false-pos-
itive and false-negative rates were lower than those
found in overall patients. Specificity and negative pre-
dictive value were extremely high (93% and 90%,
respectively). Thus, the reliability of CT scanning in
this low-risk subgroup was high in detecting the popu-
lation without mediastinal node involvement. However,
CT scanning was not reliable in diagnosing mediastinal
node involvement because sensitivity and positive pre-
dictive value were extremely low (6% and 8%, respec-
tively; Table IX).
Discussion
Mediastinal node involvement is a very important
prognostic factor in patients with potentially resectable
NSCLC.14,15 Several studies have suggested that induc-
tion chemotherapy or chemoradiation followed by sur-
gical resection results in pathologic down-staging and
better long-term survival in patients with N2 dis-
ease.16-18 Therefore, accurate preoperative evaluation
of the mediastinal nodes is important in deciding
NSCLC treatment strategy.
The CT scan is a routine examination for the diagno-
sis and locoregional staging of lung cancer at most
institutes. CT scans have revealed evident reliability in
The Journal of Thoracic and
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Table II. Radiologic characteristics of tumors
Overall FP FN
No. of patients 401 57 56
Shortest dimension of lymph node, mm (mean ± SD) 7 ± 4 11 ± 2 6 ± 3
Longest dimension of lymph node, mm (mean ± SD) 11 ± 6 17 ± 4 11 ± 6
Maximum tumor dimension, mm (mean ± SD) 32 ± 16 35 ± 16 37 ± 17
Tumor location (central/peripheral) 44/357 14/43 6/50
Obstructive pneumonia, n (%) 33 (8) 10 (18) 3 (5)
Pulmonary fibrosis, n (%) 14 (3) 4 (7) 0 (0)
Atelectasis, n (%) 14 (3) 5 (9) 1 (2)
Lymph node calcification, n (%) 34 (8) 10 (18) 5 (9)
FP, False-positive scans; FN, false-negative scans.
Table III.  Relationship between clinicoradiologic factors and false-positive scans: Univariate analysis
Variable OR 95% CI P value
Age 1.03 1.00-1.07 .05
Sex (male vs female) 3.05 1.53-6.09 .002
Smoking (pack-years >40 vs ≤40) 2.36 1.34-4.16 .003
CEA* 1.82 1.00-3.29 .05
Histology (SCC vs others) 2.11 1.14-3.89 .02
Maximum tumor dimension (mm) 1.01 0.99-1.03 .2
Tumor location (central vs peripheral) 3.41 1.68-6.93 <.001
Obstructive pneumonia 2.97 1.33-6.63 .008
Pulmonary fibrosis 2.52 0.76-8.33 .1
Atelectasis 3.58 1.15-11.10 .03
Lymph node calcification 2.84 1.28-6.31 .01
OR, Odds ratio; CI, confidence interval; CEA, carcinoembryonic antigen; SCC, squamous cell carcinoma.
*Log-transformed serum CEA levels were used.
examining the primary tumor in terms of size, location,
and extrapulmonary extension.4 However, they are far
from satisfactory and less accurate than medi-
astinoscopy in node involvement evaluation.19,20
Detection of lymph node metastasis on CT scan is
based on the demonstration of lymph node enlarge-
ment. However, several investigators reported that
benign nodes might be enlarged as a result of reactive
hyperplasia, obstructive pneumonia, or atelectasis
attributable to primary tumor or prior granulomatous
disease, whereas metastatic nodes may appear normal
in size if the metastasis is microscopic.5,21,22 These fac-
tors can lead to false-positive or false-negative scans,
which impair the reliability of CT scans in detecting
node involvement. Therefore, we attempted to clarify
which clinical and radiologic factors were significantly
related to false results on CT scans.
Multivariable analysis revealed only one significant
factor of false-positive scans: central tumor location.
Mediastinal lymph nodes may be swollen reactively by
obstructive pneumonia or atelectasis associated with
the tumor.5,21 In our study, patients with obstructive
pneumonia or atelectasis were more likely to have
false-positive scans. However, once tumor location was
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Table IV.  Relationship between clinicoradiologic factors and false-positive scans: Multivariable analysis
Variable OR 95% CI P value
Age 1.03 1.00-1.07 .08
Sex (male vs female) 2.15 0.94-4.94 .07
Smoking (pack-years >40 vs ≤40) 1.08 0.54-2.19 .8
CEA* 1.24 0.63-2.44 .5
Histology (SCC vs others) 1.14 0.56-2.32 .7
Tumor location (central vs peripheral) 2.64 1.16-6.01 .02
Obstructive pneumonia 1.54 0.58-4.09 .4
Atelectasis 1.84 0.44-7.62 .4
Lymph node calcification 2.29 0.97-5.45 .06
OR, Odds ratio; CI, confidence interval; CEA, carcinoembryonic antigen; SCC, squamous cell carcinoma.
*Log-transformed serum CEA levels were used.
Table V.  Relationship between clinicoradiologic factors and false-negative scans: Univariate analysis
Variable OR 95% CI P value
Age 1.00 0.97-1.03 .9
Sex (male vs female) 0.83 0.47-1.46 .5
Smoking (pack-years >40 vs ≤40) 1.35 0.75-2.41 .3
CEA* 2.02 1.12-3.64 .02
Histology (SCC vs others) 0.90 0.44-1.82 .8
Maximum tumor dimension (mm) 1.02 1.00-1.04 .03
Tumor location (peripheral vs central) 0.97 0.39-2.41 .9
Obstructive pneumonia 0.59 0.18-2.02 .4
Atelectasis 0.46 0.06-3.62 .5
Lymph node calcification 1.07 0.40-2.89 .9
OR, Odds ratio; CI, confidence interval; CEA, carcinoembryonic antigen; SCC, squamous cell carcinoma.
*Log-transformed serum CEA levels were used.
Table VI.  Relationship between clinicoradiologic
factors and false-negative scans: Multivariable 
analysis
Variable OR 95% CI P value
CEA* 1.92 1.05-3.51 .03
Maximum tumor 
dimension (mm) 1.02 1.00-1.04 .04
OR, Odds ratio; CI, confidence interval; CEA, carcinoembryonic antigen.
*Log-transformed serum CEA levels were used.
Table VII. CT scan reliability in diagnosing mediasti-
nal node involvement: Relationship between a signifi-
cant factor of FP and FPR
No. of cases No. of FP scans FPR (%)
Tumor location
Central 44 14 32
Peripheral 357 43 12
FP, False positive; FPR, false-positive rate.
accounted for, obstructive pneumonia or atelectasis per
se did not provide additional information concerning
false-positive results. Several reports compared the
reliability of CT mediastinal evaluation between cen-
tral and peripheral tumors. Daly and associates3 report-
ed that CT detection of positive mediastinal lymph
nodes had an accuracy of 79% for central tumors and
90% for peripheral ones. Moreover, the false-positive
rate was higher in central tumors (14%) than in periph-
eral ones (5%). Our results were generally consistent
with theirs. However, our series revealed a higher false-
positive rate (32%) in the central tumor population than
that found in their series. Because these false-positive
populations can benefit from primary surgery alone, an
invasive staging procedure, such as mediastinoscopy,
may be indicated. 
Elevated serum CEA level and larger tumor dimen-
sion were significant factors of false-negative scans in
both univariate and multivariable analyses. The larger a
tumor has grown, the more normal-sized lymph nodes
may have microscopic metastases. Some investigators
reported a relationship between elevated serum CEA
levels and advanced disease or poor prognosis. The
patients with marked elevation of preoperative serum
CEA levels are highly likely to have occult metas-
tases.23-25 In patients with an elevated CEA level,
metastatic nodes may appear normal in size. The prog-
nosis of patients with false-negative scans for mediasti-
nal node involvement has been reported to be poor,
even though it was better than that of patients with true-
positive scans.26,27 The false-negative subgroup may
benefit from induction therapy, which might indicate
an invasive staging procedure.
In patients without risk factors of false results (ie,
patients with a peripheral tumor smaller than 40 mm
and an elevated serum CEA level), CT scanning was
extremely reliable in detecting the population without
mediastinal node involvement. One hundred thirty-
seven (90%) of 153 patients with clinical N0-1 disease
on CT scanning had pathologic N0-1 disease. Thus,
patients with normal CT results in this low-risk popu-
lation can proceed directly to thoracotomy. A preoper-
ative invasive staging procedure may not be indicated.
Phillips and colleagues28 reported that as prevalence of
disease decreases, the reliability of a positive result will
drop, and the reliability of a negative result will
increase. The prevalence of N2 disease in our proposed
low-risk subgroup of false results was extremely low,
which results in low reliability of CT scanning in diag-
nosing mediastinal node involvement.
In conclusion, it is not possible to accurately diag-
nose N2 disease by using lymph node size on CT scan
alone, especially in patients with a central tumor, an
abnormal serum CEA level, or a tumor 40 mm or larg-
er. A preoperative invasive staging procedure, such as
mediastinoscopy, is indicated in these populations to
decide the appropriate treatment strategy and may not
be indicated in the population of normal CT results
without any of these risk factors.
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Table VIII. CT scan reliability in diagnosing medi-
astinal node involvement: Relationship between sig-
nificant factors of FN and FNR
No. of No. of 
cases FN scans FNR (%)
Serum CEA level
≥5 ng/mL 173 31 18
<5 ng/mL 228 25 11
Maximum tumor dimension
≥10 mm 397 56 14
≥20 mm 329 51 16
≥30 mm 195 32 16
≥40 mm 104 21 20
≥50 mm 50 12 24
≥60 mm 31 8 26
≥70 mm 16 4 25
FN, False negative; FNR, false-negative rate; CEA, carcinoembryonic antigen.
Table IX.  Comparison of reliability of CT scans in
diagnosing mediastinal node involvement between




No. of patients 401 165
No. of patients with pN2 (%) 80 (20) 17 (10)
Sensitivity (%) 30 6
Specificity (%) 82 93
Accuracy (%) 72 79
PPV (%) 30 8
NPV (%) 83 90
FPR (%) 14 6
FNR (%) 14 10
pN2, Pathologic N2 disease; PPV, positive predictive value; NPV, negative
predictive value; FPR, false-positive rate; FNR, false-negative rate.
*Patients with a peripheral tumor smaller than 40 mm and a normal serum
CEA level.
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